AR and prostate carcinoma: From these data, we concluded that an AR-GSR enriched in the sub-clonal architecture of tumour C-12A was responsible for expression of a tumour-specific set of AR-V species that could support constitutive, ligand-independent AR transcriptional activity and prostate cancer cell growth.